This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pearson, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pearson, D. A.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Human Immunodeficiency Virus...

PEDIATRICS Vol. 106 No. 6 December 2000, p. e76

ELECTRONIC ARTICLE:
Predicting HIV Disease Progression in Children Using Measures of Neuropsychological and Neurological Functioning

Received Feb 14, 2000; accepted Jun 20, 2000.

Deborah A. Pearson*, Nuala M. McGrathDagger , Molly Nozyce§, Sharon L. Nicholsparallel , Claire RaskinoDagger , Pim Brouwers, Marta C. Lifschitz, , Carol J. Baker, #, Janet A. Englund, and for the Pediatric AIDS Clinical Trials 152 Study Team

From the * Department of Psychiatry and Behavioral Sciences, University of Texas-Houston Medical School, Houston, Texas; Dagger  Center for Biostatistics in AIDS Research, Harvard School of Public Health, Cambridge, Massachusetts; § Department of Pediatrics, Bronx Lebanon Hospital Center, Bronx, New York; parallel  Department of Neurosciences, University of California, San Diego, San Diego, California; and the Departments of  Pediatrics and # Microbiology and Immunology, Baylor College of Medicine, Houston, Texas.

Background.  Neuropsychological testing and 2 measures of neurological status, cortical atrophy, and motor dysfunction were assessed for their usefulness in predicting human immunodeficiency virus (HIV) disease progression in infants, children, and adolescents who participated in Pediatric AIDS Clinical Trials Group Protocol 152 (PACTG 152).

Methods.  A cohort of 722 antiretroviral therapy-naive children with symptomatic HIV infection were assessed at study entry and at later intervals. Assessments included neurodevelopmental testing, neuroradiologic imaging, and neurological examination of motor function. CD4 cell count and plasma RNA viral load also were measured.

Results.  Children with the lowest neuropsychological functioning (IQ < 70) at baseline had the highest risk for later HIV disease progression (56%), compared with those with borderline/low (IQ = 70-89) functioning (26%), or with average or above (IQ > 90) functioning (18%). This was also true of week 48 neuropsychological functioning. Motor dysfunction (especially reduced muscle mass) at entry also predicted disease progression. Furthermore, motor dysfunction and week 48 neuropsychological functioning provided predictive information beyond that obtainable from surrogate markers of HIV disease status (eg, CD4 count, HIV RNA level). Children with cortical atrophy also were at higher risk for later disease progression, but when CD4 count and RNA viral load were known, cortical atrophy information provided no additional predictive information.

Conclusions.  Measures of neuropsychological and motor function status provide unique information regarding pediatric HIV disease progression. As such, these findings have important implications for predicting long-term outcomes (eg, longevity) in pediatric patients.  Key words:  human immunodeficiency virus, children, neuropsychology, cognitive, development, cortical atrophy, motor function.